Public Company Healthcare

Roche

Switzerland

Global biotech company bringing together medicines and diagnostics to advance personalized healthcare, including differentiated medicines and leading in vitro diagnostics across major therapeutic areas.

Focus Areas
Pharmaceuticals, Diagnostics, Biotechnology
Website
www.roche.com

Tracked deals

6

6 tracked deals across 2022-2026.

Recent pace

1

1 tracked deal announced in the last 12 months.

Deal mix

Buyout

6 buyout

Roche Acquisition Volume by Year

Last 5 years

Acquisition volume by year Annual acquisition counts for the last 5 years for Roche. 1 2022 2 2023 1 2024 1 2025 ~1 est. 1 2026
Actual Full-year estimate

Supporting Data

Recent Transactions

  • Roche to Acquire PathAI to Expand AI-Powered Digital Pathology
    May 7, 2026
    Buyer
    Roche
    Target
    PathAI
    Industry
    AI & Machine Learning
    Location
    United States
    Type
    Buyout

    Roche has entered into a definitive merger agreement to acquire PathAI, a US digital pathology and AI technology company. The deal is expected to close in the second half of the year and will integrate PathAI’s AISight image management system into Roche’s Diagnostics division.

  • Roche to Acquire 89bio for Up to $3.5 Billion
    September 22, 2025
    Buyer
    Roche
    Target
    89bio, Inc.
    Industry
    Pharmaceuticals
    Location
    United States
    Type
    Buyout

    Roche has reached an agreement to acquire 89bio, a biopharmaceutical company focused on treatments for liver diseases and cardiometabolic conditions. The deal is expected to close in the fourth quarter of 2025, with an offered price of $14.50 per share in cash plus potential contingent value rights tied to performance milestones for pegozafermin.

  • Roche Acquires Poseida Therapeutics
    November 28, 2024
    Buyer
    Roche Holdings, Inc.
    Target
    Poseida Therapeutics, Inc.
    Seller
    Poseida Therapeutics stockholders
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    Roche Holdings, Inc. has agreed to acquire San Diego-based Poseida Therapeutics for $9.00 per share in cash plus a contingent value right (CVR) for up to $4.00 per share, representing an aggregate equity value of up to $1.5 billion. The acquisition will bring Poseida's non-viral gene-editing platforms, allogeneic TSCM-rich CAR-T programs and in-house GMP cell therapy manufacturing into Roche's Pharmaceuticals Division to establish a new core capability in allogeneic cell therapy.

  • Roche Acquires Carmot Therapeutics for $2.7 Billion Upfront
    December 4, 2023
    Buyer
    Roche
    Target
    Carmot Therapeutics
    Industry
    Biotechnology
    Location
    United States
    Type
    Buyout

    Carmot Therapeutics entered into a definitive merger agreement to be acquired by Roche for $2.7 billion upfront, with up to $400 million in potential milestone payments. Carmot’s shareholders will receive $2.7 billion in cash at closing, and Carmot and its employees will join the Roche Group’s Pharmaceuticals Division.

  • Roche Buys Telavant Holdings (Roivant/Pfizer) for $7.1B+
    October 26, 2023
    Buyer
    Roche
    Target
    Telavant Holdings
    Seller
    Roivant Sciences Ltd., Pfizer
    Industry
    Healthcare Services
    Type
    Buyout

    Roche entered into a definitive agreement to acquire Telavant Holdings, a company jointly owned by Roivant and Pfizer, for an upfront purchase price of $7.1 billion plus a near-term $150 million milestone payment. The deal gives Roche full rights to further develop, manufacture, and commercialize Telavant’s TL1A-directed antibody RVT-3101 in the US and Japan, with Pfizer retaining commercialization rights outside those territories.

  • Roche Acquires Good Therapeutics to Gain PD-1-regulated IL-2 Program
    September 7, 2022
    Buyer
    Roche
    Target
    Good Therapeutics
    Industry
    Biotechnology
    Location
    Washington, United States
    Type
    Buyout

    Roche has entered into a definitive merger agreement to acquire Good Therapeutics, a Seattle-based privately held biopharmaceutical company, for an upfront $250 million plus milestone payments. The deal gives Roche rights to Good Therapeutics' conditionally active PD-1-regulated IL-2 program and an exclusive right to the platform for developing PD-1-regulated IL-2 receptor agonists; the transaction is expected to close in Q3 2022 subject to HSR clearance.

Related Acquisition Pages

Biotechnology Buyers & Acquisitions 3 tracked deals by Roche. AI & Machine Learning Buyers & Acquisitions 1 tracked deal by Roche. Healthcare Services Buyers & Acquisitions 1 tracked deal by Roche. Pharmaceuticals Buyers & Acquisitions 1 tracked deal by Roche. Acquisitions in California 1 tracked deal by Roche. Acquisitions in Washington 1 tracked deal by Roche.

Related articles

Selling a company? Get in front of buyers like Roche

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →